2024
Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Komrokji R, Diez-Campelo M, Chee L, Cluzeau T, DeZern A, Fenaux P, Garcia-Manero G, Giagounidis A, Platzbecker U, Della Porta M, Santini V, Sekeres M, Zeidan A, Buckstein R, Ross M, Jiang Y, Bobba S, Hankin M, Materna C, Graham C, Thamake S, Rovaldi C, Grayson D, Salstrom J. Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS). Blood 2024, 144: 3228.1-3228.1. DOI: 10.1182/blood-2024-200797.Peer-Reviewed Original ResearchDurability of responseMyelodysplastic neoplasmsFollow-up periodTransfusion burdenProportion of participantsAdverse eventsTransfusion independenceIneffective hematopoiesisDouble-blindPlacebo-controlled phase 3 studyAchievement of transfusion independenceMultiple stages of hematopoiesisSafety follow-up periodDouble-blind treatment periodLong-term follow-up periodSeverity of adverse eventsLong-term follow-upErythroid maturation agentLow transfusion burdenSustained hematologic improvementTreatment of transfusion-dependent anemiaPlacebo-controlled studyTransfusion-dependent anemiaPhase 3 studyProgression to AML
2023
Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial
Sekeres M, Diez-Campelo M, Zeidan A, Platzbecker U, Regnault A, Creel K, Sengupta N, Wan Y, Sun L, Xia Q, Berry T, Dougherty S, Shah S, Navada S, Santini V, Valcárcel D. Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial. Blood 2023, 142: 6479. DOI: 10.1182/blood-2023-181103.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesPatient-reported outcomesHigh transfusion burdenTransfusion burdenPlacebo groupMyelodysplastic syndromeTreatment groupsFunctional assessmentCancer Therapy-AnemiaPatient-reported fatigueTransfusion independence rateChronic Illness TherapyPhase 3 trialInferior overall survivalTransfusion-dependent anemiaLeast square meansImprovement of patientsPRO end pointsComposite scorePositive mean changesQuality of lifeFACT-AnTreat populationDyspnea scoreOverall survival
2013
The Patient With Transfusion-Dependent Anemia: Diagnosis and Directed Management With Targeted Next Generation Sequencing and Copy Number Analysis
Schulz V, Maksimova Y, Lezon-Geyda K, Gallagher P. The Patient With Transfusion-Dependent Anemia: Diagnosis and Directed Management With Targeted Next Generation Sequencing and Copy Number Analysis. Blood 2013, 122: 3419. DOI: 10.1182/blood.v122.21.3419.3419.Peer-Reviewed Original ResearchTransfusion-dependent anemiaMarrow failure syndromesBone marrow failure syndromesFailure syndromeCongenital dyserythropoietic anemiaBi-allelic mutationsIron overloadHemolytic anemiaGene mutationsNext-generation sequencingDyserythropoietic anemiaComplications of anemiaBone marrow findingsMissense mutationsTargeted Next-Generation SequencingMonths of ageSame clinical phenotypeExpectant managementWorking diagnosisChronic transfusionLiver failureMarrow findingsAppropriate therapyCommon diagnosisImmunodeficiency syndromeGlucose Phosphate Isomerase Deficiency In 2 Patients With Novel Mutations Presenting As Severe Neurologic Abnormalities and Transfusion Dependent Hemolytic Anemia
Puliyel M, Gallagher P, Berdoukas V, Glader B, Coates T. Glucose Phosphate Isomerase Deficiency In 2 Patients With Novel Mutations Presenting As Severe Neurologic Abnormalities and Transfusion Dependent Hemolytic Anemia. Blood 2013, 122: 947. DOI: 10.1182/blood.v122.21.947.947.Peer-Reviewed Original ResearchEvidence of kernicterusSevere neurologic abnormalitiesHemolytic anemiaTransfusion-dependent hemolytic anemiaNeurologic symptomsNeurologic abnormalitiesGlucose phosphate isomerase deficiencyHematopoietic stem cell transplantationCentral nervous system abnormalitiesDevelopmental delayStem cell transplantationTransfusion-dependent anemiaMotor neuron diseaseNervous system abnormalitiesSurvival of neuronsNeurotrophic growth factorsMonths of ageGlobal developmental delayAcute hemolytic crisisIsomerase deficiencyAnticonvulsant therapyCerebral atrophyNeurologic deficitsNeurologic presentationNeurological deficits
2012
Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 3837. DOI: 10.1182/blood.v120.21.3837.3837.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTransfusion independenceTransfusion useMyelodysplastic syndromeRisk groupsTransfusion statusLens useObservational studyClaims dataLarge population-based observational studiesResponse rateIntermediate-risk myelodysplastic syndromesPopulation-based observational studyICD-9-CM codesCycles of therapyInitiation of lenalidomidePoor performance statusReceipt of transfusionClinical trial evidenceInitiation of treatmentAge 75 yearsTransfusion-dependent anemiaEnd of studyZIP Code-level measuresMedicare Part A
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply